Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a special wound dressing help heal stubborn leg ulcers?

NCT ID NCT07754526

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing whether adding a special wound matrix (OCM) to standard compression and routine care helps heal venous leg ulcers better than standard care alone. Adults with a venous leg ulcer will be randomly assigned to receive either the OCM plus standard care or standard care only. The study will compare changes in ulcer size and whether patients can return to normal activities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OCM Wound Matrix (a wound dressing device) used alongside compression and routine care
What this could lead to
If effective, this could offer a new way to help venous leg ulcers heal faster and more completely, potentially improving patients' quality of life and reducing the burden of long-term wound care.
What could go wrong
This is an early-stage trial, and results may not show a significant benefit over standard care. The device may not work for everyone, and there are always risks of infection or skin irritation with any wound treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 254 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. At least 18 years old 2. Women of Childbearing Potential (WOCBP) have a negative Point of Care (POC) urine pregnancy test 3. As of date of randomization, the participant has demonstrated compliance with compression regimen 4. Largest non-healing wound, if multiple wounds are present, or the single wound of interest (Index ulcer) is located between and including the knee and the ankle at or above the malleolus 5. For participants with multiple ulcers, the largest size ulcer will be selected as the Index ulcer 6. There is at least 2cm between the Index ulcer and other ulcers\[WS1.1\]\[WS1.2\] 7. Index ulcer size is between 1 cm2 and 200 cm2 8. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within (1 to 2) months of the first screening visit are acceptable: 1. Ankle-Brachial Index (ABI) ≥0.8 and ≤1.3 2. Toe-Brachial Indx ≥ 0.6 3. Transcutaneous oxygen pressure (TCOM) ≥40 mmHg 4. Pulse Volume Recording (PVR): biphasic or triphasic waveforms 9. Confirmation of venous disease by non-invasive venous studies with either Doppler confirmed venous reflux or having ≤2 clinical characteristics of venous insufficiency (varicose veins, lipodermatosclerosis, venous dermatitis, atrophie blanch, edema) 10. Willing and able to comply with study procedures, including study visits, compression and study dressing regimens (or have family member/friend willing and able), including ability of the subject to tolerate limb compression bandage. 11. Participant has read and signed the IRB-approved Informed Consent Form (ICF) before screening procedures are undertaken. 12. As of date of randomization, the participant has had routine care and compression for 4 weeks and the participant's VLU has \<50% change in measurement 13. The Index ulcer has not been treated with a topical antibiotic within the last 7 days prior to first treatment with OCM™ 1\. Sensitivity to fish products or cod liver oil allergy\[WS2.1\]\[SB2.2\] 2. Study ulcer deemed by the investigator to be caused by a medical condition other than venous insufficiency 3. Study ulcer exhibits clinical signs and symptoms of infection, as evidenced by tissue necrosis, redness, pain, and/or purulent drainage and/or receiving systemic antibiotics for the treatment of such\* 4. Study ulcer has undergone 12 or more months of continuous high-strength compression therapy over its duration. 5\. Study ulcer extends more than 50% below the malleolus 6. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the trial 7. Simultaneous use of more than one product on the Index ulcer 8. Subjects who are unable to understand the aims and objectives of the trial or have a known history of poor adherence with medical treatment 9. The presence of any condition(s) that seriously compromises the subject's ability to complete this study 10. The subject is medically unable to consent (due to head trauma, coma, etc.) or cognitively impaired (due to being mentally challenged, having Alzheimer's etc.) 11. Subjects with a Basic Mass Index (BMI) \>65 12. Current, uncontrolled opioid addiction per the investigator's opinion 13. Presence of any monophasic waveforms on segmental Arterial Doppler/Pulse Volume Recording 14. Subject is on Dialysis 15. Any active cancer other than a nonmelanoma skin cancer 16. Any previous cancer in remission for ≤1 year 17. Bone cancer or metastatic disease of the affected limb 18. Chemotherapy within the last 12 months 19. Suspicion of or confirmed malignancy by biopsy within VLU 20. Life expectancy \<6 months in the opinion of the Investigator 21. Participant has received a treatment within 28 days of screening which is known to interfere with or affect the rate and quality of wound healing (e.g., thrombolysis, systemic steroids, immunosuppressive therapy, autoimmune disease therapy, dialysis, radiation therapy, chemotherapy, revascularization surgery) to the leg, or who may receive such medications during the screening period, or who has anticipated to require such medication during the study 22. History of immunodeficiency or any illness or condition that could interfere with wound healing: * Lymphedema * end-stage renal disease * severe malnutrition * liver disease * aplastic anemia * Raynaud Syndrome * connective tissue disorder * acquired immune deficiency syndrome * HIV positive * sickle cell anemia * Untreated osteomyelitis * Hepatitis * Known acute deep venous thrombosis 23. Subject's inability to successfully tolerate compression therapy that is changed weekly 24. All females of childbearing potential who are not using a highly effective method of birth control (failure rate less that 1% per year), such as implants, injectables, combined oral contraceptives, some IUDs, practice sexual abstinence or have a vasectomized partner * Note: an ulcer that is deemed infected at Screening might be eligible for re-screening once the infection is resolved, at the Investigator's discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous leg ulcer (VLU) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ulcer of lower limbs Varicose Ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • North Shore University Hospital Wound Care Center and Pain Management Center

    Lake Success, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.